Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain

  • End date
    Dec 12, 2022
  • participants needed
  • sponsor
    University Hospital, Clermont-Ferrand
Updated on 2 March 2021
Lise Laclautre
Primary Contact
Hospital of Annecy Genevois (3.2 mi away) Contact
+10 other location


Evaluation of the efficacy and tolerance of low doses of ethosuximide in the treatment of peripheral neuropathic pain


Multicenter, randomized, double-blind, placebo-controlled therapeutic trial evaluating the efficacy and safety of low doses of ethosuximide in neuropathic pain patients.

Condition Peripheral Neuropathic Pain
Treatment Placebo, Ethosuximide
Clinical Study IdentifierNCT04431778
SponsorUniversity Hospital, Clermont-Ferrand
Last Modified on2 March 2021


Yes No Not Sure

Inclusion Criteria

Male or female (under effective contraception: pill, implant, IUD, sterilization) aged 18 years or older, suffering from peripheral neuropathic pain (DN4 4) for more than 3 months and less than 5 years, of intensity 4 on a numerical scale from 0 to 10, and whose analgesic treatment has been stable for more than a month
Patients affiliated to the French Social Security system
Patients whose free and informed consent has been obtained

Exclusion Criteria

Pregnancy (HCG+ blood) or breastfeeding
Neuropathic pain due to spinal cord or brain injury, phantom limb pain or algohallucinosis
Fibromyalgia or algodystrophy
Chronic pain syndrome that the patient cannot distinguish and/or is more intense than peripheral neuropathic pain
Patient on antiepileptic drugs (to limit the possible potentiation of adverse reactions from ethosuximide). If necessary, after agreement with the patient, a 14-day washout prior to the start of the study will be authorized for inclusion
Significant abnormalities in liver (transaminases > 3N, cholestasis) and renal (MDRD < 60 mL/min) tests
Ongoing comorbidities: cancer, neurodegenerative pathology
Severe depressive disorder in progress (as determined by the clinician), history of suicide attempts or hospitalization for depression
Diabetic patients (contraindicated due to the high sugar concentration of ethosuximide, 3g / 5 ml)
Patients who have previously received ethosuximide (epilepsy or clinical trial)
Surgery planned throughout the entire trial
Medical and surgical history incompatible with the study
Dependence on alcohol and/or drugs (for compliance purposes)
Known allergy to succinimides (ethosuximide, methsuximide, phensuximide)
Psychotic disorders
Epileptic patients
Patients benefiting from a legal protection measure (curatorship, guardianship, deprived of liberty or subject to judicial safeguard)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note